Document Fragment View

Matching Fragments

F. For cost; and G. Such other and further orders as may be considered fit and expedient in the facts of the case be passed.

3. It is contended that the petitioner No.1 is a company incorporated under the provisions of the Companies Act, 1956 and is engaged in the business of manufacturing "Paracetamol" (hereinafter be referred to as "the subject goods) in the State of Gujarat and petitioner No.2 is a shareholder of petitioner No.1 and concerned with the day to day activities of the company. Whereas, respondent No.1 is the Ministry of Commerce, Government of India and control respondent No.2, the Designated Authority (DA) is C/SCA/5278/2019 JUDGMENT functioning and respondent No.4 is a Central Board of Indirect Taxes and Customs is the Nodal National Agency Responsible for Administering Customs, GST, Central Excise, Service Tax and Narcotics in India. It is contended that respondent No.2 is the Designated Authority constituted under the provisions of Rule 3 of the Customs Tariff (Identification, Assessment and Collection of Anti- Dumping Duty on Dumped Articles and for Determination of Injury) Rules, 1995 (hereinafter be referred to as "the Rules") and carried out its duties and functioning of a quasi judicial authority as provided under Rule 6 of the Rules.

i. The public at large is already well protected through a regulatory mechanism as Paracetamol is covered under National List of essential medicine in Pharmaceutical Policy, 2015.
ii. Paracetamol is one of the cheapest API available in the country.
iii. The production of product under consideration is quite limited globally. As, about 86% of global production is in India and China only and out of which 62% of the production is in China alone, while India commands the remaining 24%. Thus, any sickness in this industry would leave the Indian users at the mercy and monopoly of the Chinese producers.
C/SCA/5278/2019 JUDGMENT vii The public at large is already well protected through a regulator mechanism as Paracetamol is covered under National List of essential medicine in Pharmaceutical Policy, 2015.
viii Paracetamol is one of the cheapest API available in the country.
By other Interested Parties:
i The anti-dumping duties against the import of subject goods are in existence for more than 17 years and the present case is not a special case where duties are required to be extended for a further period of 5 years. (Para. 54 ii) ii The majority of imports to India from subject country are under duty free schemes such as advance license. DEPB etc. run by the Govt. of India which are not subject to duty.

b. Large scale production suspension in India: As already submitted petitioner again requests the Authority to consider the fact that due to the adverse effect of the insufficient form of duty there were large scale production suspension in the country which was primarily in the last two decades (all these closures are more than 5 years old and are prior to previous extension of ADD), c. Paracetamol formulation prices are covered under DPCO and NPPA therefore no adverse effect on the consumers The NPPA regulates the prices of Paracetamol formulation and therefore even Iife the product under consideration is not a formulation, considering that the cost of the product under consideration forms majority of the cost of Paracetamol formulation, there is an automatic; check on the prices at which the producers of the product under consideration can sell the product in the market. The Authority further notes that Paracetamol .is listed under National List of Essential Medicines and it is one of the cheapest pain killer being most widely used in the Country. Thus, while the price of both formulation and bulk drug are capped, the producers of Paracetamol have been selling the product at a price listed to regulated product.